Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
The company was incorporated in 2012 and is headquartered in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.81 Decreased by -65.31% | -0.47 Decreased by -72.34% |
| Mar 14, 24 | -0.71 Decreased by -42.00% | -0.47 Decreased by -51.06% |
| Nov 13, 23 | -0.52 Increased by +1.89% | -0.45 Decreased by -15.56% |
| Aug 9, 23 | -0.41 Increased by +54.44% | -0.48 Increased by +14.58% |
| May 9, 23 | -0.49 Increased by +86.39% | -0.49 |
| Mar 6, 23 | -0.50 Increased by +71.10% | -0.57 Increased by +12.28% |
| Nov 7, 22 | -0.53 Increased by +54.31% | -0.78 Increased by +32.05% |
| Aug 4, 22 | -0.90 Increased by +15.89% | -0.85 Decreased by -5.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -71.15 M Decreased by -78.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 10.76 M Increased by +N/A% | -62.55 M Decreased by -57.31% | Decreased by -581.55% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -45.63 M Decreased by -50.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -35.12 M Increased by +28.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -39.76 M Increased by +79.96% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -39.76 M Increased by +57.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -30.23 M Increased by +51.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -49.09 M Increased by +14.19% | Decreased by N/A% Decreased by N/A% |